Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic.
|
| Abstract |
Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the cancer population previously infected and potentially immune to SARS-CoV-2. The current study is a multi-center, prospective observational study to assess the seroprevalence of SARS-CoV-2 IgG antibody in a cancer population referred for vaccination between April and June 2021. Of a total of 270 adult patients with cancer accrued, 16% reported a history of COVID-19 more than four weeks previously confirmed by PCR. At the same time, serologic positivity for SARSCoV2 IgG was found in 29% of patients prior to vaccination including nearly 20% of patients without a history of confirmed COVID-19. Seropositivity was significantly greater in females consistent with higher rates in patients with breast cancer and gynecologic cancers. A seroconversion rate of 79.5% was observed in cancer patients with a history of PCR confirmed COVID-19, less than observed in the general population. In multivariable analysis, gender and prior history of COVID-19 were both independently associated with seropositivity prior to vaccination. Follow-up is continuing of this cohort of patients with cancer following vaccination to assess antibody and clinical outcomes.
|
|---|---|
| Authors | Seyed Alireza Javadinia, Mona Ariamanesh, Maryam Nabavifard, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah, Farbod Hatami, Ahmad Ghasemi, Gary H Lyman, James S Welsh, Somayeh Ashkar Tizabi, Mansoureh Dehghani |
| Journal | Cancer investigation (Cancer Invest) Vol. 40 Issue 2 Pg. 115-123 (Feb 2022) ISSN: 1532-4192 [Electronic] England |
| PMID | 34699294 (Publication Type: Journal Article, Multicenter Study, Observational Study) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!